10-Q: Titan Pharma Narrows Losses, Advances TalenTec Merger

Titan Pharmaceuticals reported significantly reduced net losses and improved cash flow, while progressing towards a reverse merger with TalenTec and resolving Nasdaq listing compliance issues.

Summary

• Net loss for the three months ended June 30, 2025, significantly decreased to $0.7 million from $2.1 million in the prior year.
• Net loss for the six months ended June 30, 2025, improved to $1.3 million from $3.2 million in the prior year.
• Operating expenses for the three and six months ended June 30, 2025, decreased by $1.4 million and $1.9 million, respectively, primarily due to reduced personnel-related expenses.
• Cash at June 30, 2025, was $2.8 million, which management believes is sufficient to fund operations through Q2 2026.
• Stockholders' equity increased to $2.788 million at June 30, 2025, from $2.440 million at December 31, 2024, addressing a Nasdaq compliance deficiency.
• The SEC declared the Form F-4 for the proposed reverse merger with TalenTec effective on July 21, 2025, with a stockholder meeting scheduled for August 26, 2025.
• The company regained compliance with Nasdaq's annual meeting requirement by holding its 2025 Annual Meeting on June 16, 2025.
• Completed two private placements with Blue Harbour Asset Management L.L.C-FZ in April and June 2025, raising $1.0 million and $600,000, respectively, through the issuance of Series B and Series C Convertible Preferred Stock.
• Common stock outstanding increased to 1,330,234 shares as of August 11, 2025.

Sentiment

Score: 7

Explanation: The company has made significant progress in reducing losses, improving cash flow from financing, and resolving Nasdaq compliance issues. The advancement of the reverse merger with TalenTec provides a clear path forward. However, the identified material weakness in disclosure controls and the inherent uncertainties of a reverse merger temper the overall positive sentiment.

Positives

• Significant reduction in net loss for both the three-month ($0.7M vs $2.1M) and six-month ($1.3M vs $3.2M) periods ended June 30, 2025, compared to the prior year.
• Operating expenses decreased substantially due to reduced personnel-related costs, reflecting successful cost-reduction efforts.
• Regained compliance with Nasdaq's stockholders' equity requirement, with equity increasing to $2.788 million at June 30, 2025.
• Regained compliance with Nasdaq's annual meeting requirement.
• Advanced the proposed reverse merger with TalenTec, with the SEC declaring the Form F-4 effective and a stockholder meeting scheduled.
• Successfully raised $1.6 million through private placements of preferred stock with Blue Harbour, improving liquidity and equity.
• Net cash used in operating activities decreased from $2.681 million in H1 2024 to $1.547 million in H1 2025.
• Management believes current cash is sufficient to fund operations through Q2 2026, and the anticipated $4 million private placement post-merger will fund the combined entity for at least one year.

Negatives

• Disclosure controls and procedures were deemed not effective as of June 30, 2025, and December 31, 2024, due to a material weakness in internal control over financial reporting.
• The company remains subject to ongoing Nasdaq monitoring for continued compliance with the Equity Rule, with potential delisting if compliance is not maintained in future filings.
• Cash balance slightly decreased from $2.831 million at December 31, 2024, to $2.803 million at June 30, 2025.
• Increased other expenses, primarily due to higher franchise taxes, contributing to a larger net other expense compared to the prior year.

Risks

• Uncertainty regarding the completion of the proposed reverse merger with TalenTec, as it is subject to stockholder approvals and other customary conditions.
• Risk of delisting from Nasdaq if the company fails to maintain compliance with listing standards, including the minimum stockholders' equity and minimum bid price requirements.
• If delisted, common stock trading could be restricted to the over-the-counter market, potentially reducing liquidity, analyst coverage, and share price, and subjecting it to 'penny stock' rules.
• Reliance on the ability to raise additional capital when needed, with no assurance that such efforts will be successful.
• Potential difficulties or delays in product development and regulatory processes, although less relevant after the ProNeura asset sale.
• Challenges in protecting patents and other intellectual property or trade secrets.
• Material weakness identified in disclosure controls and procedures, which could affect the timely provision of material information.

Future Outlook

Management believes current cash of $2.8 million is sufficient to fund planned operations through the second quarter of 2026. Following the consummation of the proposed reverse merger with TalenTec, the combined entity, Black Titan, is expected to receive a $4 million private placement investment, which management anticipates will be sufficient to fund operations for at least one year post-closing. The company continues to explore various financing and strategic alternatives.

Management Comments

• We are exploring several financing and strategic alternatives; however, there can be no assurance that our efforts will be successful.
• Based upon the above assessment, our efforts to reduce operating costs and expenditures, and given our existing cash, projected disbursements, and the anticipated proceeds from the private placement investment upon completion of the Merger, we concluded that, at the date of filing the financial statements in this Quarterly Report on Form 10-Q for the six months ended June 30, 2025, we had sufficient cash to fund our operations for the next 12 months without additional funds.
• Our principal executive and financial officers concluded that our disclosure controls and procedures were not effective for the timely provision of material information relating to the Company... due to the identification of a material weakness in internal control over financial reporting.
• Notwithstanding the conclusion by principal executive and financial officers that the disclosure controls and procedures... were not effective... management believes that the consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q fairly present in all material respects our financial condition, results of operations and cash flows as of the dates presented.
• Management has concluded that our internal control over financial reporting was effective as of June 30, 2025.

Industry Context

Titan Pharmaceuticals has largely exited its previous pharmaceutical product development focus (ProNeura assets sold) and is now primarily a vehicle for a reverse merger with TalenTec, a strategic move common for smaller companies seeking to access public markets or pivot their business model. The company's financial performance reflects a period of significant cost reduction and restructuring in anticipation of this merger, rather than ongoing operational results from its former core business. The successful resolution of Nasdaq compliance issues is critical for maintaining market access during this transition.

Comparison to Industry Standards

• The significant reduction in operating expenses and net loss indicates a successful cost-cutting and restructuring phase, which is a positive sign for a company undergoing a strategic pivot, especially when compared to its own prior performance.
• Regaining Nasdaq compliance for stockholders' equity and annual meetings positions the company more favorably than peers facing delisting threats, demonstrating a commitment to governance and market standards.
• The proposed reverse merger with TalenTec, a private entity, is a common strategy for private companies to go public without an IPO, and for public shell companies to acquire new operating assets. The success of this strategy will depend on the underlying business of TalenTec and its ability to generate future value, which is not detailed in this filing.
• The identified material weakness in disclosure controls, despite management's assertion of effective internal control over financial reporting, suggests a need for continued vigilance and improvement in financial reporting processes, which is a critical area for public companies.

Management Changes

Corporate Governance

Legal Proceedings

• A legal proceeding initiated in 2020 by a former employee alleging wrongful termination, retaliation, infliction of emotional distress, negligent supervision, hiring and retention, and slander.
• Fedson, Inc. assumed all liabilities related to this pending employment claim as part of the Asset Purchase Agreement in September 2023.

Related Party Transactions

• Payments of approximately $2,000 in legal fees were made to a law firm operated by one of the Board members during the six months ended June 30, 2025.
• A receivable balance of approximately $143,000 from Black Titan Corporation (a related party in the proposed merger) existed as of June 30, 2025, including $81,000 in advances made during the six months ended June 30, 2025. This amount is expected to be repaid under standard terms.
• In August 2023, a $500,000 convertible promissory note was issued to Choong Choon Hau, who had acquired a significant ownership interest from a former CEO. This note was converted into 54,132 shares of common stock in March 2024.

Stakeholder Impact

• Shareholders: Potential for significant change in company direction and ownership structure due to the proposed reverse merger with TalenTec. Dilution from preferred stock conversions and future financing is a factor. Resolution of Nasdaq compliance issues is positive for maintaining market access.
• Employees: Past workforce reductions and salary scale-backs indicate a period of significant change. The new CEO's employment agreement provides stability for that role.
• Customers/Suppliers: Minimal direct impact as the company has discontinued commercial operations and sold its product assets.
• Creditors: Improved liquidity from recent capital raises and reduced operating losses may enhance the company's ability to meet its obligations.

Next Steps

• Special meeting of stockholders scheduled for August 26, 2025, to approve the reverse merger with TalenTec.
• Nasdaq will continue to monitor the company for ongoing compliance with the Equity Rule.
• Management will continue to evaluate available options to resolve the material weakness in disclosure controls and procedures.
• Black Titan Corporation is expected to receive a $4 million private placement investment upon completion of the merger.

Key Dates

Recommendation

The company has demonstrated significant progress in cost reduction and has successfully addressed immediate Nasdaq listing compliance issues, which are positive developments. The advancement of the reverse merger with TalenTec provides a clear strategic direction and potential for future growth, supported by an anticipated $4 million private placement post-merger. However, the identified material weakness in disclosure controls and the inherent uncertainties and execution risks associated with a reverse merger, particularly with a private entity whose future business details are not fully disclosed, warrant a cautious approach. Investors should hold to observe the successful completion of the merger and the performance of the combined entity before making further investment decisions.

Keywords

Titan Pharmaceuticals, TTNP, SEC Filing, 10-Q, Quarterly Report, Financial Results, Reverse Merger, TalenTec, Black Titan, Nasdaq Compliance, Stockholders Equity, Capital Raise, Preferred Stock, Blue Harbour, Biotechnology, Pharmaceuticals, Corporate Governance, Risk Factors